273 related articles for article (PubMed ID: 28923861)
1. MCT1 Inhibitor AZD3965 Increases Mitochondrial Metabolism, Facilitating Combination Therapy and Noninvasive Magnetic Resonance Spectroscopy.
Beloueche-Babari M; Wantuch S; Casals Galobart T; Koniordou M; Parkes HG; Arunan V; Chung YL; Eykyn TR; Smith PD; Leach MO
Cancer Res; 2017 Nov; 77(21):5913-5924. PubMed ID: 28923861
[TBL] [Abstract][Full Text] [Related]
2. Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer.
Polański R; Hodgkinson CL; Fusi A; Nonaka D; Priest L; Kelly P; Trapani F; Bishop PW; White A; Critchlow SE; Smith PD; Blackhall F; Dive C; Morrow CJ
Clin Cancer Res; 2014 Feb; 20(4):926-937. PubMed ID: 24277449
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma.
Noble RA; Bell N; Blair H; Sikka A; Thomas H; Phillips N; Nakjang S; Miwa S; Crossland R; Rand V; Televantou D; Long A; Keun HC; Bacon CM; Bomken S; Critchlow SE; Wedge SR
Haematologica; 2017 Jul; 102(7):1247-1257. PubMed ID: 28385782
[TBL] [Abstract][Full Text] [Related]
4. In Vivo Anticancer Activity of AZD3965: A Systematic Review.
Silva A; Antunes B; Batista A; Pinto-Ribeiro F; Baltazar F; Afonso J
Molecules; 2021 Dec; 27(1):. PubMed ID: 35011413
[TBL] [Abstract][Full Text] [Related]
5. Cellular Uptake of MCT1 Inhibitors AR-C155858 and AZD3965 and Their Effects on MCT-Mediated Transport of L-Lactate in Murine 4T1 Breast Tumor Cancer Cells.
Guan X; Rodriguez-Cruz V; Morris ME
AAPS J; 2019 Jan; 21(2):13. PubMed ID: 30617815
[TBL] [Abstract][Full Text] [Related]
6. In Vitro and In Vivo Efficacy of AZD3965 and Alpha-Cyano-4-Hydroxycinnamic Acid in the Murine 4T1 Breast Tumor Model.
Guan X; Morris ME
AAPS J; 2020 Jun; 22(4):84. PubMed ID: 32529599
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of metabolism-related biomarkers in non-Hodgkin lymphoma - MCT1 as potential target in diffuse large B cell lymphoma.
Afonso J; Pinto T; Simões-Sousa S; Schmitt F; Longatto-Filho A; Pinheiro C; Marques H; Baltazar F
Cell Oncol (Dordr); 2019 Jun; 42(3):303-318. PubMed ID: 30790227
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of monocarboxylate transporter-1 (MCT1) by AZD3965 enhances radiosensitivity by reducing lactate transport.
Bola BM; Chadwick AL; Michopoulos F; Blount KG; Telfer BA; Williams KJ; Smith PD; Critchlow SE; Stratford IJ
Mol Cancer Ther; 2014 Dec; 13(12):2805-16. PubMed ID: 25281618
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance.
Quanz M; Bender E; Kopitz C; Grünewald S; Schlicker A; Schwede W; Eheim A; Toschi L; Neuhaus R; Richter C; Toedling J; Merz C; Lesche R; Kamburov A; Siebeneicher H; Bauser M; Hägebarth A
Mol Cancer Ther; 2018 Nov; 17(11):2285-2296. PubMed ID: 30115664
[TBL] [Abstract][Full Text] [Related]
10. Monocarboxylate transporter 1 blockade with AZD3965 inhibits lipid biosynthesis and increases tumour immune cell infiltration.
Beloueche-Babari M; Casals Galobart T; Delgado-Goni T; Wantuch S; Parkes HG; Tandy D; Harker JA; Leach MO
Br J Cancer; 2020 Mar; 122(6):895-903. PubMed ID: 31937921
[TBL] [Abstract][Full Text] [Related]
11. Dual Inhibition of the Lactate Transporters MCT1 and MCT4 Is Synthetic Lethal with Metformin due to NAD+ Depletion in Cancer Cells.
Benjamin D; Robay D; Hindupur SK; Pohlmann J; Colombi M; El-Shemerly MY; Maira SM; Moroni C; Lane HA; Hall MN
Cell Rep; 2018 Dec; 25(11):3047-3058.e4. PubMed ID: 30540938
[TBL] [Abstract][Full Text] [Related]
12. Catastrophic ATP loss underlies a metabolic combination therapy tailored for
Dalton KM; Lochmann TL; Floros KV; Calbert ML; Kurupi R; Stein GT; McClanaghan J; Murchie E; Egan RK; Greninger P; Dozmorov M; Ramamoorthy S; Puchalapalli M; Hu B; Shock L; Koblinski J; Glod J; Boikos SA; Benes CH; Faber AC
Proc Natl Acad Sci U S A; 2021 Mar; 118(13):. PubMed ID: 33762304
[No Abstract] [Full Text] [Related]
13. Monocarboxylate transporter 1 and 4 inhibitors as potential therapeutics for treating solid tumours: A review with structure-activity relationship insights.
Puri S; Juvale K
Eur J Med Chem; 2020 Aug; 199():112393. PubMed ID: 32388280
[TBL] [Abstract][Full Text] [Related]
14. MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4.
Hong CS; Graham NA; Gu W; Espindola Camacho C; Mah V; Maresh EL; Alavi M; Bagryanova L; Krotee PAL; Gardner BK; Behbahan IS; Horvath S; Chia D; Mellinghoff IK; Hurvitz SA; Dubinett SM; Critchlow SE; Kurdistani SK; Goodglick L; Braas D; Graeber TG; Christofk HR
Cell Rep; 2016 Feb; 14(7):1590-1601. PubMed ID: 26876179
[TBL] [Abstract][Full Text] [Related]
15. Cancer metabolism, stemness and tumor recurrence: MCT1 and MCT4 are functional biomarkers of metabolic symbiosis in head and neck cancer.
Curry JM; Tuluc M; Whitaker-Menezes D; Ames JA; Anantharaman A; Butera A; Leiby B; Cognetti DM; Sotgia F; Lisanti MP; Martinez-Outschoorn UE
Cell Cycle; 2013 May; 12(9):1371-84. PubMed ID: 23574725
[TBL] [Abstract][Full Text] [Related]
16. CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors.
Le Floch R; Chiche J; Marchiq I; Naiken T; Ilc K; Murray CM; Critchlow SE; Roux D; Simon MP; Pouysségur J
Proc Natl Acad Sci U S A; 2011 Oct; 108(40):16663-8. PubMed ID: 21930917
[TBL] [Abstract][Full Text] [Related]
17. Mitochondria as new therapeutic targets for eradicating cancer stem cells: Quantitative proteomics and functional validation via MCT1/2 inhibition.
Lamb R; Harrison H; Hulit J; Smith DL; Lisanti MP; Sotgia F
Oncotarget; 2014 Nov; 5(22):11029-37. PubMed ID: 25415228
[TBL] [Abstract][Full Text] [Related]
18. Hodgkin lymphoma: A complex metabolic ecosystem with glycolytic reprogramming of the tumor microenvironment.
Mikkilineni L; Whitaker-Menezes D; Domingo-Vidal M; Sprandio J; Avena P; Cotzia P; Dulau-Florea A; Gong J; Uppal G; Zhan T; Leiby B; Lin Z; Pro B; Sotgia F; Lisanti MP; Martinez-Outschoorn U
Semin Oncol; 2017 Jun; 44(3):218-225. PubMed ID: 29248133
[TBL] [Abstract][Full Text] [Related]
19. The anti-tumour agent lonidamine is a potent inhibitor of the mitochondrial pyruvate carrier and plasma membrane monocarboxylate transporters.
Nancolas B; Guo L; Zhou R; Nath K; Nelson DS; Leeper DB; Blair IA; Glickson JD; Halestrap AP
Biochem J; 2016 Apr; 473(7):929-36. PubMed ID: 26831515
[TBL] [Abstract][Full Text] [Related]
20. MACC1 mediates chemotherapy sensitivity of 5-FU and cisplatin via regulating MCT1 expression in gastric cancer.
Wang C; Wen Z; Xie J; Zhao Y; Zhao L; Zhang S; Liu Y; Xue Y; Shi M
Biochem Biophys Res Commun; 2017 Apr; 485(3):665-671. PubMed ID: 28235486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
